Rook AH - Search Results

1

Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M, Rook AH. Kim EJ, et al. Among authors: rook ah. J Clin Invest. 2005 Apr;115(4):798-812. doi: 10.1172/JCI24826. J Clin Invest. 2005. PMID: 15841167 Free PMC article. Review.

2

New biologic agents for the treatment of cutaneous T-cell lymphoma.

Vittorio CC, Junkins-Hopkins JM, McGinnis KS, Shapiro M, Wysocka M, Zaki MH, French LE, Rook AH. Vittorio CC, et al. Among authors: rook ah. Recent Results Cancer Res. 2002;160:321-8. doi: 10.1007/978-3-642-59410-6_37. Recent Results Cancer Res. 2002. PMID: 12079230 Review.

3

Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod.

Suchin KR, Junkins-Hopkins JM, Rook AH. Suchin KR, et al. Among authors: rook ah. Arch Dermatol. 2002 Sep;138(9):1137-9. doi: 10.1001/archderm.138.9.1137. Arch Dermatol. 2002. PMID: 12224972 No abstract available.

4

Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.

Shapiro M, Rook AH, Lehrer MS, Junkins-Hopkins JM, French LE, Vittorio CC. Shapiro M, et al. Among authors: rook ah. J Am Acad Dermatol. 2002 Dec;47(6):956-61. doi: 10.1067/mjd.2002.124816. J Am Acad Dermatol. 2002. PMID: 12451388 No abstract available.

5

Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.

Rook AH, Junkins-Hopkins JM, McGinnis KS, Wysocka M, Richardson SK, Budgin JB, Everitts S, Vittorio CC. Rook AH, et al. Adv Dermatol. 2002;18:29-43. Adv Dermatol. 2002. PMID: 12528401 Review.

6

Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma.

Kari L, Loboda A, Nebozhyn M, Rook AH, Vonderheid EC, Nichols C, Virok D, Chang C, Horng WH, Johnston J, Wysocka M, Showe MK, Showe LC. Kari L, et al. Among authors: rook ah. J Exp Med. 2003 Jun 2;197(11):1477-88. doi: 10.1084/jem.20021726. J Exp Med. 2003. PMID: 12782714 Free PMC article.

7

Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.

Richardson SK, McGinnis KS, Shapiro M, Lehrer MS, Kim EJ, Vittorio CC, Junkins Hopkins JM, Rook AH. Richardson SK, et al. Among authors: rook ah. J Cutan Med Surg. 2003 Jul-Aug;7(4 Suppl):8-12. doi: 10.1007/s10227-003-5002-0. J Cutan Med Surg. 2003. PMID: 12958701 No abstract available.

8

The use of cytokines, fusion proteins and antibodies to treat cutaneous T-cell lymphoma.

Rook AH, McGinnis KS, Richardson SK, Budgin JB, Wysocka M, Benoit BM, Hopkins JM, Vittorio CC. Rook AH, et al. Dermatol Ther. 2003;16(4):331-6. doi: 10.1111/j.1396-0296.2003.01645.x. Dermatol Ther. 2003. PMID: 14686976 Review.

9

Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.

McGinnis KS, Junkins-Hopkins JM, Crawford G, Shapiro M, Rook AH, Vittorio CC. McGinnis KS, et al. Among authors: rook ah. J Am Acad Dermatol. 2004 Mar;50(3):375-9. doi: 10.1016/j.jaad.2003.10.669. J Am Acad Dermatol. 2004. PMID: 14988678

10

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15.

Wysocka M, Benoit BM, Newton S, Azzoni L, Montaner LJ, Rook AH. Wysocka M, et al. Among authors: rook ah. Blood. 2004 Dec 15;104(13):4142-9. doi: 10.1182/blood-2004-03-1190. Epub 2004 Aug 24. Blood. 2004. PMID: 15328153 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

258 results

Search Page

Filters